Phase I Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study With Multiple Ascending Doses of ORM-12741.
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2009
At a glance
- Drugs ORM 12741 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Orion
- 25 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 25 Sep 2009 Actual patient number (51) added as reported by ClinicalTrials.gov.